Press release
Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference, which takes place from August 5th through 8th.\n\n\nDetails for presentations related to GB001, an oral DP2 antagonist for eosinophilic asthma and chronic rhinosinusitis (CRS), are as follows:\n\n\nSession Type: Thematic Poster Session\nSession Title: Asthma Clinical Trials (B31)\nAbstract Number: 3019\nPoster Code: P378\nPoster Title: Pharmacokinetics, Pharmacodynamics, and Safety of GB001 in Healthy Non-Asian, Non-Japanese Asian and Japanese Subjects\nLink: https://bit.ly/2P36tKx\n\n\nSession Type: Thematic Poster Session\nSession Title: Asthma Subphenotypes, Targets and Therapeutics (D69)\nAbstract Number: 7417\nPoster Number: P409\nPoster Title: GB001 Is a Differentiated Potent Prostaglandin D2 Antagonist with Long Receptor Residence Time and Extended Pharmacodynamic Efficacy\nLink: https://bit.ly/2X6YZdR\n\n\nSession Type: Thematic Poster Session\nSession Title: Asthma Epidemiology (D31)\nAbstract Number: 6478\nPoster Number: P368\nPoster Title: An Assessment of Asthma Control in a Real-World Setting\nLink: https://bit.ly/333BNBd\n\n\nDetails for a presentation related to GB002, an inhaled PDGFR inhibitor for pulmonary arterial hypertension (PAH), are as follows:\n\n\nSession Type: Poster Discussion Session\nSession Title: Up-To-Date PAH Assessment and Management (B27)\nAbstract Number: 2907\nPoster Number: P903\nPoster Title: Phase 1a Randomized Double-Blind Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Studies of Orally Inhaled GB002 in Healthy Adult Subjects\nLink: https://bit.ly/3f7GqfT\n\n\nAbout Gossamer Bio\n\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire...